Investigating how depression treatment affects gut health and brain function in people with HIV
Official title: Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
Run by Florida International University · NCT05136703 · Data updated 2026-11-12
This study is testing whether treating depression with therapy can improve gut health and brain function in people living with HIV.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Florida International University Academic / other |
| Locations | 2 sites (Coral Gables, Florida and 1 other locations) |
| Status | Recruiting |
| Started | August 30, 2022 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT05136703 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 or older who are HIV positive, have a current diagnosis of major depressive disorder, and are stable on their antidepressant regimen.
✕Probably not a fit
Patients who are actively untreated for major mental illness or have received cognitive-behavioral therapy for depression in the past two years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized controlled trial aims to explore the effects of cognitive-behavioral therapy for adherence and depression (CBT-AD) on the gut microbiome, immune system, and brain function in individuals living with HIV. The study will assess how reductions in depressive symptoms can lead to changes in the microbiome-gut-brain axis, potentially improving neurobehavioral outcomes. Participants will undergo fMRI scans and biospecimen collection to evaluate the biological mechanisms involved in these changes. The research seeks to establish a causal relationship between depression treatment and its effects on health in the context of HIV.
Why it matters
Potential benefit: If successful, this study could lead to improved mental and physical health outcomes for individuals living with HIV by integrating psychological treatment with biological health improvements.
How similar studies have gone: While the integration of cognitive-behavioral therapy and microbiome research is innovative, similar studies have shown promising results in understanding the interplay between mental health and biological factors.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or older 2. Speaks and reads English 3. Verified HIV+ status with antiretroviral medications bearing his/her name 4. Current diagnosis on Major Depressive Disorder (MDD) using a structured clinical interview (DIAMOND) or Hamilton Rating Scale for Depression scores of 7 or greater 5. If prescribed antidepressants, on a stable regimen and dose for at least 2 months 6. Suppressed HIV viral load (\< 200 copies/mL) 7. Able to complete Functional Magnetic Resonance Imaging (fMRI) scans (i.e., no claustrophobia, no metal implants, no pacemaker, and BMI \< 40) Exclusion Criteria: 1. Unable to provide informed consent 2. Active, untreated major mental illness 3. Pregnancy at baseline 4. Received CBT for depression in the past 2 years 5. 5\. Otherwise eligible but does not complete the run-in period that includes the baseline assessment, biospecimen collection, the fMRI visit, and a separately scheduled randomization visit
Where it's running
-
University of Miami Neuroimaging Facility
Coral Gables, Florida, United States Recruiting -
Care Resource - Midtown Miami
Miami, Florida, United States Recruiting
Study contacts
- Principal investigator: Adam W Carrico, PhD — Florida International University
- Study coordinator: Adam W Carrico, PhD
- Email: acarrico@fiu.edu
- Phone: (305) 348-7887
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap
This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.
-
Smartphone-supported single-session psychotherapy for postpartum depression
A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.
-
Mindful Smartphone Use: A Mindfulness-Based Program for Teens with Sleep and Mood Challenges
This study tests Mindwire, a mindfulness-based program, to see if it helps teens with problematic phone use who also have depression or anxiety.
-
Tele-based wellbeing centres for women's mental health in Bangladesh
A randomized trial tests whether tele-counselling for depression and anxiety in Bangladeshi women is as effective as in-person counselling.
-
Remote monitoring for adults with depression using ThIA Suivi
This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.
-
HBOT to see if it helps cognition and well‑being in first responders with prior brain injury
This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.